Pharmacoeconomics of Biologic Therapy
| Autor: | Allan T. Luskin, Don A. Bukstein |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Complete data
medicine.medical_specialty Cost-Benefit Analysis Immunology Disease 03 medical and health sciences Pharmacoeconomics 0302 clinical medicine medicine Immunology and Allergy Humans 030212 general & internal medicine Economics Pharmaceutical Intensive care medicine Asthma Quality of Health Care Biological Products Cost–benefit analysis business.industry Health Care Costs medicine.disease United States Biologic Agents Biological Therapy 030228 respiratory system Relevant cost Personalized medicine business |
| Zdroj: | Immunology and allergy clinics of North America. 37(2) |
| ISSN: | 1557-8607 |
| Popis: | Novel biologic agents have allowed clinicians to achieve improved patient outcomes. Appropriate pharmacoceconomic analyses demand evaluation of all relevant costs, including the treatments, the disease and comorbidities, and costs of alternative treatments, including their short- and long-term side effects. Only with complete data can the value of therapies be correctly estimated. By assessing costs, pharmacoeconomic studies complement studies of efficacy and safety, helping to determine the relationships of treatment and outcome. This article provides a broad framework for understanding and evaluating published economic analyses and identifying the key costs and benefits caring for patients with asthma and other immune diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|